title: Effect of mycophenolate mofetil (Cell Cept) in the treatment of immune glomerulopathies.
abstract: OBJECTIVE
  To study the effect of mycophenolate mofetil (Cell Cept) in treating patients with various types of chronic glomerulonephritis and other immune nephropathies.
  
  
  METHODS
  Between 2000 and 2003 we treated 35 patients (18 women, 17 men) with Cell Cept (La Roche). In 32 patients the diagnosis was confirmed by kidney biopsy (immunofluorescence, light and electron microscopy).
  
  
  RESULTS
  Treatment with Cell Cept was very successful in 22 of the patients in the study (62.86%). Proteinuria was significantly reduced and firmly maintained well below 0.5 g/l; serum protein levels were elevated to normal values, the edemas disappeared. In 12 patients the drug had a good effect: there was a significant reduction of proteins in the urea within 1.2 - 2.0 g/l, an increase of total protein and albumins in plasma but after three months of treatment. The therapy was with no effect only in one patient with primary amyloidosis of kidneys.
  
  
  CONCLUSIONS
  Treatment with mycophenolate mofetil (Cell Cept) is an alternative modality for the management of immune glomerulopathies resistant to conventional and pulse pathogenetic therapeutic regimens. It can be a treatment of first choice.
authors.affiliation: II-nd Department of Internal Medicine, Medical University - Plovdiv, Bulgaria.
authors.forename: Dimitar J
authors.initials: DJ
authors.lastname: Dimitrakov
authors.forename: Dimitar G
authors.initials: DG
authors.lastname: Nikolov
authors.forename: Jordan D
authors.initials: JD
authors.lastname: Dimitrakov
authors.forename: Toma B
authors.initials: TB
authors.lastname: Despotov
authors.forename: Emil P
authors.initials: EP
authors.lastname: Kumchev
authors.forename: Zdravka S
authors.initials: ZS
authors.lastname: Tzvetkova
authors.forename: Edward E
authors.initials: EE
authors.lastname: Tilkian
authors.forename: Stefka M
authors.initials: SM
authors.lastname: Pandeva
authors.forename: Dora L
authors.initials: DL
authors.lastname: Chatalbasheva
authors.forename: Valeri D
authors.initials: VD
authors.lastname: Tzekov
authors.forename: Beniamin L
authors.initials: BL
authors.lastname: Anavi
mesh_terms: D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D008297:Male; D008856:Microscopy, Fluorescence; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use; D011507:Proteinuria / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D011239:Prednisolone; D009173:Mycophenolic Acid